312 lines
8.4 KiB
Markdown
312 lines
8.4 KiB
Markdown
---
|
|
title: "Spatial Omics Analysis - Report Template"
|
|
task: ""
|
|
lineage_type: import
|
|
upstream_source: https://github.com/mims-harvard/ToolUniverse/blob/e2520a96/skills/tooluniverse-spatial-omics-analysis/report-template.md
|
|
upstream_sha: e2520a96
|
|
imported_at: 2026-06-26
|
|
prompt_class: prompt
|
|
upstream_changes: accepted
|
|
author: upstream
|
|
validated: false
|
|
---
|
|
|
|
# Spatial Omics Analysis - Report Template
|
|
|
|
## Report File Structure
|
|
|
|
Create this file at the start: `{tissue}_{disease}_spatial_omics_report.md`
|
|
|
|
```markdown
|
|
# Spatial Multi-Omics Analysis Report: {Tissue Type}
|
|
|
|
**Report Generated**: {date}
|
|
**Technology**: {platform}
|
|
**Tissue**: {tissue_type}
|
|
**Disease Context**: {disease or "Normal tissue"}
|
|
**Total SVGs Analyzed**: {count}
|
|
**Spatial Domains**: {count}
|
|
**Spatial Omics Integration Score**: (to be calculated)
|
|
|
|
---
|
|
|
|
## Executive Summary
|
|
|
|
(2-3 sentence synthesis of key spatial findings - fill after all phases complete)
|
|
|
|
---
|
|
|
|
## 1. Tissue & Disease Context
|
|
|
|
### Tissue Information
|
|
| Property | Value | Source |
|
|
|----------|-------|--------|
|
|
| Tissue type | | |
|
|
| Disease | | |
|
|
| Expected cell types | | HPA |
|
|
|
|
### Disease Identifiers (if applicable)
|
|
| System | ID | Source |
|
|
|--------|-----|--------|
|
|
|
|
**Sources**: (tools used)
|
|
|
|
---
|
|
|
|
## 2. Spatially Variable Gene Characterization
|
|
|
|
### 2.1 Gene ID Resolution
|
|
| Gene Symbol | Ensembl ID | Entrez ID | UniProt | Function | Source |
|
|
|-------------|------------|-----------|---------|----------|--------|
|
|
|
|
### 2.2 Tissue Expression Patterns
|
|
| Gene | Tissue Expression | Specificity | Source |
|
|
|------|-------------------|-------------|--------|
|
|
|
|
### 2.3 Subcellular Localization
|
|
| Gene | Location | Confidence | Source |
|
|
|------|----------|------------|--------|
|
|
|
|
### 2.4 Disease Associations
|
|
| Gene | Disease | Score | Evidence | Source |
|
|
|------|---------|-------|----------|--------|
|
|
|
|
**Sources**: (tools used)
|
|
|
|
---
|
|
|
|
## 3. Pathway Enrichment Analysis
|
|
|
|
### 3.1 STRING Functional Enrichment
|
|
| Category | Term | Description | P-value | FDR | Genes | Source |
|
|
|----------|------|-------------|---------|-----|-------|--------|
|
|
|
|
### 3.2 Reactome Pathway Analysis
|
|
| Pathway ID | Name | P-value | FDR | Genes Found | Total Genes | Source |
|
|
|------------|------|---------|-----|-------------|-------------|--------|
|
|
|
|
### 3.3 GO Biological Processes
|
|
| GO Term | Description | P-value | FDR | Genes | Source |
|
|
|---------|-------------|---------|-----|-------|--------|
|
|
|
|
### 3.4 GO Molecular Functions
|
|
| GO Term | Description | P-value | FDR | Genes | Source |
|
|
|---------|-------------|---------|-----|-------|--------|
|
|
|
|
### 3.5 GO Cellular Components
|
|
| GO Term | Description | P-value | FDR | Genes | Source |
|
|
|---------|-------------|---------|-----|-------|--------|
|
|
|
|
### Pathway Summary
|
|
- Top enriched pathways:
|
|
- Key biological processes:
|
|
- Spatial pathway implications:
|
|
|
|
**Sources**: (tools used)
|
|
|
|
---
|
|
|
|
## 4. Spatial Domain Characterization
|
|
|
|
### Domain: {domain_name}
|
|
|
|
#### Marker Genes
|
|
| Gene | Function | Pathways | Source |
|
|
|------|----------|----------|--------|
|
|
|
|
#### Enriched Pathways (domain-specific)
|
|
| Pathway | P-value | FDR | Genes | Source |
|
|
|---------|---------|-----|-------|--------|
|
|
|
|
#### Cell Type Signature
|
|
| Cell Type | Marker Genes Present | Confidence |
|
|
|-----------|---------------------|------------|
|
|
|
|
#### Biological Interpretation
|
|
(Narrative interpretation of this domain)
|
|
|
|
(Repeat for each domain)
|
|
|
|
### 4.N Domain Comparison
|
|
| Feature | Domain 1 | Domain 2 | Domain 3 |
|
|
|---------|----------|----------|----------|
|
|
| Top pathway | | | |
|
|
| Cell types | | | |
|
|
| Disease relevance | | | |
|
|
|
|
**Sources**: (tools used)
|
|
|
|
---
|
|
|
|
## 5. Cell-Cell Interaction Inference
|
|
|
|
### 5.1 Protein-Protein Interactions (STRING)
|
|
| Protein A | Protein B | Score | Type | Source |
|
|
|-----------|-----------|-------|------|--------|
|
|
|
|
### 5.2 Ligand-Receptor Pairs
|
|
| Ligand | Receptor | Domain (Ligand) | Domain (Receptor) | Evidence | Source |
|
|
|--------|----------|-----------------|-------------------|----------|--------|
|
|
|
|
### 5.3 Signaling Pathways
|
|
| Pathway | Components in Data | Spatial Distribution | Source |
|
|
|---------|--------------------|---------------------|--------|
|
|
|
|
### 5.4 Interaction Network Summary
|
|
- Key interaction hubs:
|
|
- Cross-domain interactions:
|
|
- Predicted cell-cell communication axes:
|
|
|
|
**Sources**: (tools used)
|
|
|
|
---
|
|
|
|
## 6. Disease & Therapeutic Context
|
|
|
|
### 6.1 Disease Gene Overlap
|
|
| Gene | Disease Association Score | Evidence Type | Source |
|
|
|------|--------------------------|---------------|--------|
|
|
|
|
### 6.2 Druggable Targets in Spatial Domains
|
|
| Gene | Domain | Tractability | Modality | Approved Drugs | Source |
|
|
|------|--------|-------------|----------|----------------|--------|
|
|
|
|
### 6.3 Drug Mechanisms Relevant to Spatial Targets
|
|
| Drug | Target | Mechanism | Phase | Source |
|
|
|------|--------|-----------|-------|--------|
|
|
|
|
### 6.4 Clinical Trials
|
|
| NCT ID | Title | Target Gene | Phase | Status | Source |
|
|
|--------|-------|-------------|-------|--------|--------|
|
|
|
|
### Therapeutic Summary
|
|
- Druggable genes in disease regions:
|
|
- Approved therapies:
|
|
- Pipeline drugs:
|
|
- Novel opportunities:
|
|
|
|
**Sources**: (tools used)
|
|
|
|
---
|
|
|
|
## 7. Multi-Modal Integration
|
|
|
|
### 7.1 Protein-RNA Concordance (if protein data available)
|
|
| Gene/Protein | RNA Pattern | Protein Pattern | Concordance | Source |
|
|
|-------------|-------------|-----------------|-------------|--------|
|
|
|
|
### 7.2 Subcellular Context
|
|
| Gene | mRNA Location (spatial) | Protein Location (HPA) | Concordance | Source |
|
|
|------|------------------------|----------------------|-------------|--------|
|
|
|
|
### 7.3 Metabolic Context (if metabolomics available)
|
|
| Gene | Metabolic Pathway | Metabolites Detected | Spatial Pattern | Source |
|
|
|------|-------------------|---------------------|-----------------|--------|
|
|
|
|
**Sources**: (tools used)
|
|
|
|
---
|
|
|
|
## 8. Immune Microenvironment (if relevant)
|
|
|
|
### 8.1 Immune Cell Markers
|
|
| Cell Type | Marker Genes | Spatial Domain | Source |
|
|
|-----------|-------------|----------------|--------|
|
|
|
|
### 8.2 Immune Checkpoint Expression
|
|
| Checkpoint | Gene | Expression Pattern | Source |
|
|
|------------|------|--------------------|--------|
|
|
|
|
### 8.3 Tumor-Immune Interface (if cancer)
|
|
| Feature | Finding | Evidence | Source |
|
|
|---------|---------|----------|--------|
|
|
|
|
### Immune Summary
|
|
- Immune infiltration pattern:
|
|
- Key immune checkpoints:
|
|
- Immunotherapy implications:
|
|
|
|
**Sources**: (tools used)
|
|
|
|
---
|
|
|
|
## 9. Literature & Validation Context
|
|
|
|
### 9.1 Literature Evidence
|
|
| PMID | Title | Relevance | Year | Source |
|
|
|------|-------|-----------|------|--------|
|
|
|
|
### 9.2 Known Spatial Patterns
|
|
(Known tissue architecture/zonation from literature)
|
|
|
|
### 9.3 Validation Recommendations
|
|
| Priority | Gene/Target | Method | Rationale |
|
|
|----------|-------------|--------|-----------|
|
|
| High | | IHC / smFISH | |
|
|
| Medium | | IF / ISH | |
|
|
|
|
**Sources**: (tools used)
|
|
|
|
---
|
|
|
|
## Spatial Omics Integration Score
|
|
|
|
| Component | Points | Max | Details |
|
|
|-----------|--------|-----|---------|
|
|
| SVGs provided | | 5 | |
|
|
| Disease context | | 5 | |
|
|
| Spatial domains | | 5 | |
|
|
| Cell types | | 5 | |
|
|
| Multi-modal data | | 5 | |
|
|
| Literature context | | 5 | |
|
|
| Pathway enrichment | | 10 | |
|
|
| Cell-cell interactions | | 10 | |
|
|
| Disease mechanism | | 10 | |
|
|
| Druggable targets | | 10 | |
|
|
| Cross-database validation | | 10 | |
|
|
| Clinical validation | | 10 | |
|
|
| Literature support | | 10 | |
|
|
| **TOTAL** | | **100** | |
|
|
|
|
**Score**: XX/100 - [Tier]
|
|
|
|
---
|
|
|
|
## Completeness Checklist
|
|
|
|
- [ ] Gene ID resolution complete
|
|
- [ ] Tissue expression patterns analyzed (HPA)
|
|
- [ ] Subcellular localization checked (HPA)
|
|
- [ ] Pathway enrichment complete (STRING + Reactome)
|
|
- [ ] GO enrichment complete (BP + MF + CC)
|
|
- [ ] Spatial domains characterized individually
|
|
- [ ] Domain comparison performed
|
|
- [ ] Protein-protein interactions analyzed (STRING)
|
|
- [ ] Ligand-receptor pairs identified
|
|
- [ ] Disease associations checked (OpenTargets)
|
|
- [ ] Druggable targets identified (OpenTargets tractability)
|
|
- [ ] Drug mechanisms reviewed
|
|
- [ ] Multi-modal integration performed (if data available)
|
|
- [ ] Immune microenvironment characterized (if relevant)
|
|
- [ ] Literature search completed
|
|
- [ ] Validation recommendations provided
|
|
- [ ] Spatial Omics Integration Score calculated
|
|
- [ ] Executive summary written
|
|
- [ ] All sections have source citations
|
|
|
|
---
|
|
|
|
## References
|
|
|
|
### Data Sources Used
|
|
| # | Tool | Parameters | Section | Items Retrieved |
|
|
|---|------|------------|---------|-----------------|
|
|
|
|
### Database Versions
|
|
- OpenTargets: (current)
|
|
- STRING: v12.0
|
|
- Reactome: (current)
|
|
- HPA: (current)
|
|
- GTEx: v10
|
|
```
|